Skip to main content
OpenTrials
Completed

NCT Number: NCT01135511

A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease

The purpose of the study is to evaluate dose-response, efficacy and safety of CP-690,550 eye drops in patients with dry eye disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Dry Eye Syndromes Eye Diseases Lacrimal Apparatus Diseases

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Pfizer Investigational Site, Ichinomiya, Aichi-ken, Japan

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjective symptoms of dry eye for at least 6 months
  • Signs of moderate to severe dry eye (corneal staining score and schirmer test without anesthesia)

Exclusion criteria

  • Women who are nursing, pregnant or planning pregnancy during the study
  • Participation in other studies within 30 days of screening visit
  • Ocular disorders that may confound interpretation of study results

Treatment and study plan

CP-690,550 Eye drops

Drug

Ophthalmic topical solution, low dose, dosed once/day, 8 weeks

CP-690,550 Eye drops-vehicle

Drug

Ophthalmic topical solution, vehicle, dosed once/day, 8 weeks

Sodium Hyaluronate

Drug

Ophthalmic topical solution, dosed 6 times/day, 8 weeks

Primary outcomes

  1. Changes in Corneal Staining Scores for Study Eye From Baseline at Week 8

    Time frame: Baseline, Week 8

    Based on the National Eye Institute (NEI) dry eye clinical trials workshop, the cornea was divided into 5 different zones. Each corneal zone was graded independently using a 0 to 3 grading scale:0=none, 1=slight, 2=moderate, 3=severe. Sum of scores of each zone led to total score. Total score range: 0 to 15, higher score indicated greater staining. Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change: score at observation minus score at baseline. Negative change from baseline indicated improvement.

Secondary outcomes

  1. Changes in Corneal Staining Scores for Study Eye From Baseline

    Time frame: Baseline, Week 1, 2 and 4

    Based on the National Eye Institute (NEI) dry eye clinical trials workshop, the cornea was divided into 5 different zones. Each corneal zone was graded independently using a 0 to 3 grading scale:0=none, 1=slight, 2=moderate, 3=severe. Sum of scores of each zone led to total score. Total score range: 0 to 15, higher score indicated greater staining. Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change: score at observation minus score at baseline. Negative change from baseline indicated improvement.

  2. Percentage of Participants Demonstrating 100 Percent Clearing of Corneal Staining for Study Eye

    Time frame: Week 1, 2, 4 and 8

    Percentage of participants demonstrating corneal staining score = 0 which indicates no damage in corneal surface.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

  3. Changes in Conjunctival Staining Scores (Interpalpebral) for Study Eye From Baseline

    Time frame: Baseline, Week 1, 2, 4 and 8

    Based on the Oxford grading system, the bulbar conjunctiva of each eye was divided into 2 different zones (nasal and temporal). The nasal and temporal bulbar conjunctival zones were each graded independently using a 6-point scale (0 [Absent] to 5 [Severe]). Total score ranged from 0 (Absent) to 10 (severe), higher score=higher damage to eyes due to dryness. Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change = scores at observation minus score at baseline. Negative change from baseline indicated improvement.

  4. Changes in Tear Break Up Time (TBUT) for Study Eye From Baseline

    Time frame: Baseline, Week 1, 2, 4 and 8

    TBUT is the interval between the last complete blink and the first appearance of a dry spot, or disruption in the tear film. Using a stopwatch, the time between last complete blink and first appearance of dry spot was recorded.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change: value at observation minus value at baseline. Positive change from baseline indicated improvement.

  5. Changes in Schirmer Test Values Without Anesthesia for Study Eye From Baseline

    Time frame: Baseline, Week 1, 2, 4 and 8

    The Schirmer test without anesthesia was used to estimate tear flow stimulated reflexly by insertion of a filter paper strip into the conjunctival sac. The length of wetting (distance from the notch) was recorded in millimeters (to the nearest 0.5 mm). If the wetting line was oblique, the halfway point was used.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change: value at observation minus value at baseline. Positive change from baseline indicated improvement.

  6. Percentage of Participants Who Achieve ≥10 mm Schirmer Test Value Without Anesthesia for Study Eye

    Time frame: Week 1, 2, 4 and 8

    The Schirmer test without anesthesia was used to estimate tear flow stimulated reflexly by insertion of a filter paper strip into the conjunctival sac. The length of wetting (distance from the notch) was recorded in millimeters (to the nearest 0.5 mm). If the wetting line was oblique, the halfway point was used.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

  7. Number of Participants Who Increase of ≥10 mm From Baseline in Schirmer Test Value Without Anesthesia for Study Eye

    Time frame: Week 1, 2, 4 and 8

    The Schirmer test without anesthesia was used to estimate tear flow stimulated reflexly by insertion of a filter paper strip into the conjunctival sac. The length of wetting (distance from the notch) was recorded in millimeters (to the nearest 0.5 mm). If the wetting line was oblique, the halfway point was used.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

  8. Changes in the Ocular Comfort Index (OCI) Total Score From Baseline

    Time frame: Baseline, Week 1, 2, 4 and 8

    The OCI is a validated instrument developed to measure the frequency and intensity of 6 common dry eye symptoms: dryness, grittiness, stinging, eye tiredness, pain, and itching. It contains 12 questions, each measured on a 7-point rating scale (0 [Never] to 6 [Always], or 0 [Never had it] to 6 [Severe]). Total score ranged from 0 (none) to 72 (severe symptoms). A higher score indicates more severe dry eye symptoms.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change: score at observation minus score at baseline. Negative change from baseline indicated improvement.

  9. Number of Participants Demonstrating at Least ≥3 Unit Decrease in Ocular Comfort Index (OCI) Total Score From Baseline

    Time frame: Week 1, 2, 4 and 8

    The OCI is a validated instrument developed to measure the frequency and intensity of 6 common dry eye symptoms: dryness, grittiness, stinging, eye tiredness, pain, and itching. It contains 12 questions, each measured on a 7-point rating scale (0 [Never] to 6 [Always], or 0 [Never had it] to 6 [Severe]). Total score ranged from 0 (none) to 72 (severe symptoms). A higher score indicates more severe dry eye symptoms.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change = scores at observation minus score at baseline. Negative change from baseline indicated improvement.

  10. Changes in the Ocular Surface Disease Index (OSDI) Total Score From Baseline

    Time frame: Baseline, Week 1, 2, 4 and 8

    The OSDI is a validated instrument for ocular surface diseases, measuring the ocular symptoms, vision-related function, and environmental triggers.

    The 12 items of the OSDI questionnaire were graded on a scale of 0 [none of the time] to 4 [all of the time]. The total OSDI score was then calculated on the basis of the following formula: OSDI=[(sum of scores for all questions answered) × 100]/[(total number of questions answered) × 4].

    The OSDI is scored on a scale of 0 to 100, with higher scores representing greater disability.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change: score at observation minus score at baseline. Negative change from baseline indicated improvement.

  11. Changes in the Ocular Surface Disease Index (OSDI) Subscale Score From Baseline: Ocular Symptoms

    Time frame: Baseline, Week 1, 2, 4 and 8

    The OSDI is a validated instrument for ocular surface diseases, measuring the ocular symptoms, vision-related function, and environmental triggers.

    The 12 items of the OSDI questionnaire were graded on a scale of 0 [the none of time] to 4 [all of the time]. The subscale OSDI score was then calculated on the basis of the following formula: OSDI=[(sum of scores for questions 1 to 3 answered) × 100]/[(total number of questions 1 to 3 answered) × 4].

    The OSDI is scored on a scale of 0 to 100, with higher scores representing greater disability.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change: score at observation minus score at baseline. Negative change from baseline indicated improvement.

  12. Changes in the Ocular Surface Disease Index (OSDI) Subscale Score From Baseline: Vision-Related Function

    Time frame: Baseline, Week 1, 2, 4 and 8

    The OSDI is a validated instrument for ocular surface diseases, measuring the ocular symptoms, vision-related function, and environmental triggers.

    The 12 items of the OSDI questionnaire were graded on a scale of 0 [none of the time] to 4 [all of the time]. The subscale OSDI score was then calculated on the basis of the following formula: OSDI=[(sum of scores for questions 4 to 9 answered) × 100]/[(total number of questions 4 to 9 answered) × 4].

    Thus, the OSDI is scored on a scale of 0 to 100, with higher scores representing greater disability.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change: score at observation minus score at baseline. Negative change from baseline indicated improvement.

  13. Changes in the Ocular Surface Disease Index (OSDI) Subscale Score From Baseline: Environmental Triggers

    Time frame: Baseline, Week 1, 2, 4 and 8

    The OSDI is a validated instrument for ocular surface diseases, measuring the ocular symptoms, vision-related function, and environmental triggers.

    The 12 items of the OSDI questionnaire were graded on a scale of 0 [none of the time] to 4 [all of the time]. The subscale OSDI score was then calculated on the basis of the following formula: OSDI=[(sum of scores for questions 10 to 12 answered) × 100]/[(total number of questions 10 to 12 answered) × 4].

    The OSDI is scored on a scale of 0 to 100, with higher scores representing greater disability.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change: score at observation minus score at baseline. Negative change from baseline indicated improvement.

  14. Percentage of Participants Demonstrating ≥10 Unit Decrease in Ocular Surface Disease Index (OSDI) Total Score From Baseline

    Time frame: Week 1, 2, 4 and 8

    The OSDI is a validated instrument for ocular surface diseases, measuring the ocular symptoms, vision-related function, and environmental triggers.

    The 12 items of the OSDI questionnaire were graded on a scale of 0 [none of the time] to 4 [all of the time]. The total OSDI score was then calculated on the basis of the following formula: OSDI=[(sum of scores for all questions answered) × 100]/[(total number of questions answered) × 4].

    The OSDI is scored on a scale of 0 to 100, with higher scores representing greater disability.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

  15. Number of Participants Evaluable for Time to Achievement of 100% Clearing of Corneal Staining for Study Eye

    Time frame: Week 8

    Based on the National Eye Institute (NEI) dry eye clinical trials workshop, the cornea was divided into 5 different zones. Each corneal zone was graded independently using a 0 to 3 grading scale. The maximum possible staining score is 15, higher score indicated greater staining.

    100% Clearing of Corneal Staining means corneal staining score = 0. Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

  16. Number of Participants Evaluable for Time to Achievement of ≥10 mm Schirmer Wetting Score Without Anesthesia for Study Eye

    Time frame: Week 8

    The Schirmer test without anesthesia was used to estimate tear flow stimulated reflexly by insertion of a filter paper strip into the conjunctival sac.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

  17. Number of Participants Evaluable for Time to Achievement of ≥3 Unit Decrease in OCI Scores

    Time frame: Week 8

    The OCI is a validated instrument developed to measure the frequency and intensity of 6 common dry eye symptoms: dryness, grittiness, stinging, eye tiredness, pain, and itching. It contains 12 questions, each measured on a 7-point rating scale (0 [Never] to 6 [Always], or 0 [Never had it] to 6 [Severe]). Negative change from baseline indicated improvement. Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

  18. Number of Participants With Ocular Adverse Events (AEs)by Severity

    Time frame: 8 weeks

    Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Ocular AEs are the events which are localized in the ocular region. Participants with multiple occurrences of an AE within a category were counted once within the category.

  19. Number of Participants With Nonocular Adverse Events (AEs) by Severity

    Time frame: 8 weeks

    Counts of participants who had treatment-emergent nonocular AEs, defined as newly occurring or worsening after first dose. Participants with multiple occurrences of an AE within a category were counted once within the category.

  20. Summary of Maximum Severity of Ocular Tolerability Assessments Post Baseline for Study Eye: Number of Participants in Each Severity Scale

    Time frame: 8 weeks

    Ocular tolerability was assessed for the 5 symptoms (burning sensation, blurred vision, ocular discomfort, pain, tearing), based on a 4-point severity scale (none, minor, moderate, and severe).

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

Other outcomes

  1. Change in Expression of Inflammatory Markers on Conjunctival Cells From Baseline: Human Leukocyte Antigen-DR Antibody Bound Per Cell for Study Eye

    Time frame: Baseline, Week 4 and 8

    The average level of HLA-DR expression per cell was reported as HLA-DR antibody bound per cell (ABC).

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change = value at observation minus value at baseline.

  2. Change in Expression of Inflammatory Markers on Conjunctival Cells From Baseline: Percentage of Human Leukocyte Antigen (HLA)-DR Positive for Study Eye

    Time frame: Baseline, Week 4 and 8

    Percentage of conjunctival epithelial cells that were positive with HLA-DR expression was calculated as HLA-DR Positive.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

  3. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Apolipoprotein C-3

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  4. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Interleukin-18

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  5. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Interleukin-6

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  6. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Interleukin-7

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  7. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Interleukin-8

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  8. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Monocyte Chemotactic Protein 1

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  9. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Interleukin-12 P40/P35 Heterodimer (IL-12P70)

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  10. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Interleukin-1 Beta

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  11. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Interleukin-1 Receptor Antagonist

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  12. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Interleukin-23

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  13. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Matrix Metalloproteinase-3

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  14. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Matrix Metalloproteinase-9

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  15. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Vascular Endothelial Growth Factor

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  16. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Alpha-1 Antitrypsin

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  17. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Interleukin-17A

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  18. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Chemokine (C-X-C Motif) Ligand 10 (CXCL10) (Alias Gamma-Interferon Inducible Protein 10: IP10)

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  19. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Chemokine (C-X-C Motif) Ligand 9 (CXCL9) (Alias Monokine Induced by Gamma Interferon: MIG)

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  20. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Chemokine ( C-C Motif) Ligand 20 (CCL20) (Alias Macrophage Inflammatory Protein 3 Alpha: MIP3A)

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  21. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Chemokine (C-C Motif) Ligand 5 (CCL5) (Alias Regulated on Activation, Normal T Cell Expressed, and Secreted: RANTES)

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  22. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Tissue Inhibitor of Metalloproteinase 1 (TIMP-1)

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  23. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Epidermal Growth Factor

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  24. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Albumin

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  25. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Mucin 5AC

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  26. Number of Participants Evaluated for Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Mucin 4

    Time frame: Week 4 and 8

    Number of analyzed with sufficient quantity for analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

  27. Change in the Biomarker in Tear Fluid for Study Eye From Baseline - Mucin 16 Carbohydrate Antigen 125

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  28. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Mucin 1

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  29. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Lipocalin 1

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

  30. Change in the Biomarker in Tear Fluid for Study Eye From Baseline -Total Protein

    Time frame: Baseline, Week 4 and 8

    Analysis of biomarkers which were immune and inflammatory mediators such as cytokines, chemokines and matrix metalloproteinases.

    Results from study eye are reported. The study eye was defined as the eye with the worse (higher) corneal staining score at baseline.

    Change= value at visit minus value at baseline.

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A Phase II, Prospective, Randomized, Double Masked/Investigator Masked, Vehicle And Comparator (Sodium Hyaluronate Eye Drops) Controlled, Dose Ranging Study Of CP-690,550 Eye Drops In Subjects With Dry Eye Disease

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Jun 2, 2010
Registry last updated
May 7, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.